2019
Approval cerabone® & maxresorb® in Argentina
–
Approval maxresorb® in Australia
–
Approval cerabone®, collprotect® membrane, Jason® membrane, mucoderm®, maxresorb® & maxresorb® inject in India
–
Approval Jason® membrane, cerabone® & mucoderm® in Philippines
–
MDSAP (Medical Device Single Audit Program) scope extension to Brazil and Japan as well as recertification for Australia, Canada and United States
–
botiss participation at 4 ITI congresses
2018
Approval cerabone® in USA
–
Approval Jason® membrane in USA
–
Scheduled market launch in USA, Australia, Brazil
–
MDSAP (Medical Devise Single Audit Program)-certification including ISO 13485:2016
–
botiss participation at 3 ITI congresses
–
Fourth bone & tissue days World Congress in Barcelona, Berlin and Warsaw
2017
CE mark approval permamem® and cerabone®
–
botiss participation at ITI World Symposium in Basel
2016
Third bone & tissue days World Congress in Berlin
–
Pre-launch of first products in the USA
–
Straumann takes over exclusive distribution of botiss products in Germany
2015
Market launch of maxgraft® cortico
–
botiss participation at 8 ITI congresses worldwide
2014
Pharmaceutical approval for maxgraft® and for maxgraft® bonebuilder
–
Second bone & tissue days World Congress in Berlin with 800 participants
–
Worldwide cooperation with Straumann in the field of regenerative products
2013
Exclusive cooperation with the Charité tissue bank for the dental regeneration
2012
First bone & tissue days World Congress in Berlin
2011
CE mark approval for mucoderm® and for maxresorb® inject
–
Acquisition of Cells+Tissubank Austria
2010
CE mark approval for collprotect® membrane
2009
CE mark approcal for Jason® membrane
2008
Establishment of botiss medical AG
2007
CE mark approval for maxresorb®
2002
CE mark approval for cerabone®, employed since 2006 in the dental field